Corporate presentation - 2018 (Public) - Syndermix
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Corporate presentation 2018 (Public)
SynDermix profile
Who we are What we do How we do it
Founded in 2009, SynDermix is a Swiss clinical- We focus on developing frontier treatments Largely a virtual company, our model is to in-
stage biotechnology company financed by for disorders affecting the epithelial tissues of license promising new medicines and medical
private investors and currently preparing to list the human body (the in and out skin), with a devices, outsource their development and
on the SIX Swiss Stock Exchange priority on areas of unmet medical need enter into partnerships for market access
2
Disclaimer: Forward-looking statements
This document contains certain statements that are not historical facts The Company is an emerging clinical-stage healthcare company
and may be forward-looking statements that are subject to a variety of with higher investment risk and higher potential compared to
risks and uncertainties. There are a number of important factors that larger or more established companies. If one or more of these risks
could cause actual results to differ materially from those projected or or uncertainties materialises, or if underlying assumptions prove
suggested in any forward-looking statement made by SynDermix (“the incorrect, the Company's actual results may vary materially from
Company”). These factors include (but are not limited to): those expected, estimated or projected. Given these risks and
------------------ uncertainties, potential investors should not place any reliance
on forward-looking statements
i. The Company's and/or the Company's partners’ ability to
successfully complete product research and development Without limiting the generality of the foregoing, no assurance is
given as to when the Company’s products will be launched or
ii. The Company's and/or the Company's partners’ ability to obtain licensed or whether that launch or licensing will be commercially
required governmental approvals (including product and patent successful, and words such as "may", "will", "to", "expect", "plan",
approvals; the impact of industry and government regulation; the "believe", "anticipate", "intend", "could", "would", "estimate" or
difficulty of predicting regulatory authority approvals; the "continue" or the negative or other variations thereof or comparable
regulatory environment and changes in the health policies and terminology is intended to identify forward-looking statements
structures of various countries)
iii. The acceptance and demand for new products and technologies, Neither the Company nor its directors undertake any obligation to
and the Company's ability to attract and/or maintain update forward-looking statements or risk factors other than as
manufacturing, sales, distribution and marketing partners required by applicable law, whether as a result of new information,
future events or otherwise
iv. The Company's and/or the Company's partners’ ability to develop
and commercialise products before its competitors and the impact
of competitive products and pricing; the availability and pricing of
ingredients used in the manufacturing of products and
uncertainties regarding market acceptance of innovative products,
be they newly launched, currently being sold or in development. In
addition, significant fluctuations in financial results may occur as a
result of the timing of milestone payments and the timing of costs
and expenses related to the Company's research and development
programme
3
1. The Company
4
Company history
5
About SynDermix
Innovating to defend the body’s frontiers
At SynDermix, we focus on developing products that improve the health and wellbeing of the body’s outside
defence system, the inner and outer skin (the mucosal barriers that line the gastrointestinal, respiratory and
urogenital tracts and the integumentary system)
Health
We hold intellectual property in the area of three innovative platform technologies: plant lectins, nitric oxide
and vibration therapies; these technologies provide the scientific basis for a robust pipeline of
biopharmaceuticals and medical devices whose core therapeutic areas include: ENT (ears, nose and throat),
cancer supportive care, gastroenterology and dermatology,
Wellcare
Complementing our focus on healthcare products, where appropriate, SynDermix leverages the non-
prescription health and beauty benefits of its technologies to drive a dynamic wellcare pipeline; in this way,
we put to good use all aspects of the discoveries made in our pipeline cycle and we are able to make a greater
contribution to overall wellness
6
About SynDermix
Our mission
At SynDermix, we make it our mission to work in strategic partnerships to develop life-transforming
treatments in areas of unmet medical need
Our vision
Our vision is to become a global player in lasting innovation, to continually make a positive difference in the
health and lives of patients worldwide
Our values
We value integrity, dedication and fairness; we believe that success is achieved by people with a diverse range
of talents and through mutual, synergistic efforts; we view continued innovation as the answer to unmet and
changing healthcare needs, and we strive for sustainability in our pipeline cycle as well as in our collaborations
7
Business model
SynDermix is to a large extent a virtual company; we operate a lean structure, which leverages the complementary expertise
of a seasoned executive team, a small number of full-time employees, and a broad network of contracted service providers
and key opinion leaders
8
Company organisation
Board of Directors
Compensation Committee Audit Committee Corporate Governance
Dieter Hemmer
CEO
Konstantinos
Rolf Küng Carlos Camozzi
Efthymiopoulos
Director: Administration, Director: Clinical, Regulatory &
Director: Medical Marketing &
Finance & Controlling Orphan Drugs
Business Development
Tony Lockett [TBD] Jessica Kourniakti
Director: Research & Director: Regulatory Affairs Associate Director: Strategy &
Manufacturing Marketing
Johanna Wolf Anastasia Mantalidi Julian Heinrich
Associate Director: Strategic Associate Director: QA & Administration & Data
Development & Implementation Manufacturing Management
Ebora SA (A. Benito)
Investor relations
9
Managing Directors
Dieter Hemmer — Chief Executive Officer Konstantinos Efthymiopoulos, PharmD, PhD, MBA —
15 years’ senior executive experience at Nestlé as Head of the Medical Marketing & Business Development
Strategic Business Unit (Nestlé Professional Food Services) and Over 25 years’ international experience in big pharma, biotech and VC-
Chairman of the Pro Gastronomia Nestlé Foundation. Prior to backed companies (Farmitalia-Carlo Erba, Glaxo/GlaxoWelcome,
Nestlé, he spent 22 years in a number of senior executive positions Serono, Eurand, Funxional Therapeutics, Index Ventures) at increasingly
with Lufthansa, including Head of Global Inflight Service and senior levels that culminated in CSO, CEO and board positions. He is
Managing Director for Lufthansa Service (LSG) Asia. BSc in currently the Chairman of the Board of Synaffix BV and Biopôle SA
Economics from FHS Heidelberg and management education at
INSEAD, London Business School and IMD
Rolf Küng, MBA — Finance & Controlling Anthony Lockett, MD, PhD, MBA
A Swiss Certified Accountant and co-founder of the Institute For — Research & Manufacturing
Innovative Trading (IFIT) in 1998. 17 years’ experience in auditing Over 25 years’ experience in the pharmaceutical and medical devices
(Touché Ross, Deloitte Haskins & Sells, Grant Thornton and others). industry. For the last 13 years he has been part of a team of consultants
Has been a director and CEO of several companies within the IFIT advising clients on the regulatory and clinical strategy for product
Group with a focus on business projects in Europe and overseas, development and has acted as a CMO for an AIM listed company. He is
and is currently a consultant to ARIA Capital Management with also a Professor at King’s College, London
offices in the UK, UAE, Greece and Switzerland
Carlos Camozzi, MD, PhD, MBA
— Clinical & Regulatory
Over 25 years’ international senior management experience in the
biopharmaceutical industry (Roche, American Cyanamid, Mepha
AG, Orphan Europe, UniQure, Orphazyme). Successfully led several
regulatory achievements with both the EMA and the FDA. He is a
permanent expert in the European Commission for Eureka and
H2020 grant frames, and an expert in rare diseases and orphan
drugs
10Board of Directors
Thomas Mehrling, MD PhD — Chairman of the Board Hans Peter Frick, Dr. iur LL.M — Member of the Board
CEO of EDO GmbH, Basel, with more than 17 years’ experience in Senior Vice-President and Chief Legal Officer of the Nestlé Group from
the pharmaceutical industry. During his tenure as Director of 1992 to 2011; served for 6 years on the Boards of Galenica SA and Vifor
Oncology (2011-13) with Mundipharma, two major products were Pharma SA and chaired its Audit and Risk Committees, both
successfully launched in Europe: DepoCyte® and Levact® companies active in the healthcare markets. Past experiences include
(Ribomustin®, Treanda®). A certified Pharmacist with a Ph.D. in Chief Executive of AIBD (now ICMA), then the designated stock
pharmacology and a certified physician with an M.D. in haemato- exchange for the secondary trading of international securities, Legal
oncology (both from Frankfurt University). Counsel for Hewlett Packard Europe and private practice.
Dieter Hemmer — Delegate of the Board Wolfgang Werlé — Member of the Board
(15 years’ senior executive experience at Nestlé as Head of the Founder of the international investments company Quantrum AG with
Strategic Business Unit (Nestlé Professional Food Services) and over 20 years’ experience on the Boards of companies in a range of
Chairman of the Pro Gastronomia Nestlé Foundation. Spent 22 years industries, including food and catering, medical tourism and luxury
in a number of senior executive positions with Lufthansa, including hospitality, and asset management. Past positions include: Board
Head of Global Inflight Service and Managing Director for Lufthansa member of Swiss Post, Vice-Chairman of the specialty food company
Service (LSG) Asia. Aryzta (2008), CEO of the Hiestand Group and of SAirRelations.
Kevin P. Cox, PhD — Member of the Board Hermann A. Wirz, BA — Member of the Board
Over 25 years’ experience in the life science industry, covering a wide An over 40-year career trajectory with Nestlé Group in different
range of sectors; served as CEO of numerous high growth positions of responsibility, including leadership roles in finance,
biotechnology businesses and has extensive experience in strategy, accounting and operations in a number of South American
corporate development, M&A, financing and joint ventures. Has countries, the UK and Spain; past Board member of Nestlé Capital
developed strong links to government, funding bodies and Advisers, Intercona Reinsurance AG, Alcon Inc. (US listed) and SIX
academia. (Swiss Stock Exchange).
11Our collaborators
SynDermix outsources its IP, manufacturing, preclinical/clinical and regulatory activities to the Company’s valued corporate
partners; this is part of our lean and cost-effective structure, ensuring that each stream in our pipeline cycle benefits from the
expertise and experience of world specialists
IP, regulatory & corporate Manufacturing Clinical
Intellectual property Biotechnologies Microbiology contract
company, London manufacturer, research organisation
Billingham, UK (CRO), Glasgow
Patent and law office,
Budapest Professional Worldwide laboratory
inventors, Biel testing services
Intellectual property
specialists, Leeds Pharmaceutical CRO & drug
development development services,
Regulatory consulting services, Cheshire Princeton, NJ
and services, Munich
International and CRO & integrated
commercial lawyers, Zurich scientific services, Biel
Market research
company, London
122. Our Portfolio
13Portfolio overview
Our portfolio is currently based on three proprietary technology platforms:
Lectins Nitric oxide Vibration therapies
Lectins are carbohydrate-binding Nitric oxide is a natural molecule that is Vibration therapy involves applying
proteins that are considered to have a produced by and is essential to the localised or whole-body vibration to
wide range of therapeutic applications biological functions of the human body the body of the patient with a medical
in humans, particularly due to their – a signaling molecule with powerful device; it has been shown to help treat
demonstrated antimicrobial, antitumor anti-inflammatory, antimicrobial and respiratory and musculoskeletal
and healing activities vasoregulatory effects disorders, chronic wounds and pain
14Next steps
Plant lectins
• First wellcare product manufactured and clinically tested to be partnered
• Regulatory strategy kick-off and Phase II/III trial in oral mucositis
• Proof of principle across a wide spectrum of diseases
/ Nitric oxide
• Proof of principle in wound-healing and other dermatological and urogenital
disorders
Vibration therapies
• Confirmatory clinical trial in chronic rhinosinusitis
• Migraine project (SDX-3103) kick-off
Intellectual property
• Expansion and strengthening of patent portfolio in all three platforms
Investors
• Investment activities as a bridge to Swiss stock exchange listing
15Lectins pipeline according to indication
R&D Pre-Clinical Phase I Phase II Phase III Approval
Oral mucositis SDX-1301
Inflammatory
SDX-13
bowel diseases
Pulmonary diseases
SDX-13
(e.g. cystic fibrosis)
Skin diseases SDX-13
Eye disorders SDX-13
Cancer SDX-13/14
Gastrointestinal SDX-13
ulceration
Wound healing SDX-14
(e.g. diabetic foot ulcers) Accelerated review
Cardiometabolic SDX-13/14 Regulatory strategy TBD
16Vibration therapies, nitric oxide & wellcare pipelines
R&D Pre-Clinical Phase I Phase II Phase III Approval
Chronic rhinosinusitis SDX-3101
Migraine SDX-3103
Wound-healing SDX-3104
Wound-healing SDX-2101
Other dermatological SDX-21
indications
Wellcare Énielle
Vibration therapies
Nitric oxide
Wellcare product
17Registered offices Operating offices SynDermix AG SynDermix Management AG Buochserstrasse 2 Voltastrasse 61 CH-6370 Stans CH-8044 Zurich Contact us Tel +41 44 366 40 16 info@syndermix.ch www.syndermix.ch A member of the Swiss Biotech Association and the BioIndustry Association 18
You can also read
